Related Experiment Video

Updated: Feb 6, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.6K

Optimized processing for pathogen inactivation of double-dose buffy-coat platelet concentrates: maintained in vitro

S Ohlsson1, B Diedrich1,2, M Uhlin1,3

  • 1Department of Clinical Immunology and Transfusion Medicine (KITM), Karolinska University Hospital, Stockholm, Sweden.

Vox Sanguinis
|August 30, 2018
PubMed
Abstract

Insights

Pathogen inactivation (PI) using alternate supplier (AS) plastic sets maintained platelet quality. This method allows for increased buffy coat pooling without compromising safety or efficacy over seven days.

Area of Science:

  • Blood banking and transfusion medicine
  • Platelet processing and storage
  • Infectious disease control in blood products

Background:

  • Efficient pathogen inactivation (PI) can increase buffy coat pooling for platelet concentrates.
  • This study evaluates platelets processed using alternate supplier (AS) plastic materials.

Purpose of the Study:

  • To assess the in vitro quality of platelets processed with AS plastic materials and a new pooling set.
  • To determine if AS sets maintain platelet quality over a 7-day storage period.

Main Methods:

  • Platelet concentrates were prepared from pooled buffy coats using new 8-lead pooling sets and PI processing sets with AS plastics.
  • Platelets were treated with the INTERCEPT Blood System and stored for up to 7 days.
  • In vitro quality parameters, including glucose, lactate, CD62P, CD42b, JC-positive cells, PAC-1, sCD40L, and PDGF, were analyzed.

Main Results:

  • All tested units met European guidelines.
  • AS sets significantly improved glucose reserves, reduced lactate production, and decreased CD62P and CD42b expression.
  • AS sets maintained JC-positive cells and platelet integrin activation (PAC-1) throughout storage.

Conclusions:

  • Pathogen inactivation using AS sets and the new pooling set effectively maintains platelet in vitro quality for 7 days.
  • This approach supports increased buffy coat pooling for platelet preparation without compromising quality.
Keywords:
Plateletsbuffy-coatpathogen reduction

More Related Videos

Isolation of Human Neutrophils from Whole Blood and Buffy Coats08:12

Isolation of Human Neutrophils from Whole Blood and Buffy Coats

Published on: September 17, 2021

21.4K
Generation of Induced Pluripotent Stem Cells from Frozen Buffy Coats using Non-integrating Episomal Plasmids10:52

Generation of Induced Pluripotent Stem Cells from Frozen Buffy Coats using Non-integrating Episomal Plasmids

Published on: June 5, 2015

13.6K

Related Concept Videos

X-Inactivation01:58

X-Inactivation

The human X chromosome contains over ten times the number of genes as in the Y chromosome. Since males have only one X chromosome, and females have two, one might expect females to produce twice as many of the proteins, with undesirable results.
42.3K
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
256
Storage01:23

Storage

A schema is a mental framework that helps individuals organize and interpret information. Schemata, formed from previous experiences, influence how we process new information: how we encode it, the inferences we make, and how we retrieve it. For instance, a schema for what a typical classroom looks like might include desks, a teacher's desk, a whiteboard, and students in such an environment. This expectation helps us quickly understand and navigate new classrooms without needing to analyze...
416
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
227
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
11.5K
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
234